Bristol-Myers Squibb Company Announces Expiration of Hart-Scott-Rodino Review Period for Acquisition of KOSAN Biosciences, Inc.

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the Hart-Scott-Rodino review period for its tender offer for Kosan Biosciences Incorporated (NASDAQ: KOSN) (“Kosan”) has expired.

Back to news